Akebia Therapeutics, Inc. (AKBA) Stock Analysis and Metrics

Akebia Therapeutics

NASDAQ: AKBA

$1.22 ▲ +0.00 (+0.00%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap328.47 Mn

P/E-16.01

P/S1.41

Div. Yield0.00

Total Debt (Qtr)48.89 Mn

Revenue Growth (1y) (Qtr)-6.61

Add ratio to table…

About

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company that develops and commercializes therapeutics for patients affected by kidney disease. The company focuses on addressing anemia and mineral metabolism disorders that arise as complications of chronic kidney disease. Its current portfolio consists of two approved oral products, Vafseo for anemia in dialysis patients and Auryxia for phosphorus control and iron deficiency anemia in dialysis and non dialysis dependent patients. In addition to its commercial products, Akebia maintains a pipeline of investigational agents that target rare kidney disorders such as focal segmental glomerulosclerosis, immunoglobulin A nephropathy, complement mediated glomerulopathy and lupus nephritis. The company also explores early stage hypoxia inducible factor modifiers for acute conditions like cardiac surgery related acute kidney injury and acute respiratory distress syndrome.

Akebia Therapeutics generates revenue primarily from the sale of Vafseo and Auryxia in the United States and from royalty and milestone payments under its licensing collaborations. Vafseo was launched in the United States in January 2025 and addresses an estimated $1 billion market for anemia treatment in dialysis patients based on current erythropoiesis stimulating agent pricing. Auryxia has been marketed since 2018 and historically contributed meaningful revenue before facing loss of exclusivity in March 2025 and anticipated generic competition thereafter. The company receives upfront payments, developmental milestones and tiered royalties from partners such as Medice for the European Economic Area, Tanabe Pharma Corporation for Japan and Asian markets, and CSL Vifor for the United States prior to the termination of that agreement. These collaborations provide additional cash flows and expand the geographic reach of its products without requiring direct commercial infrastructure in those territories.

Akebia Therapeutics positions itself as a leader in the kidney community by offering oral alternatives to injectable therapies that have long dominated anemia management. In the anemia market its main competitors include Amgen with epoetin alfa and Johnson & Johnson with darbepoetin alfa, as well as CSL Vifor which markets methoxy PEG epoetin beta and Roche which distributes similar agents outside the United States. In the phosphate binder market Auryxia competes with products from Sanofi such as Renagel and Renvela, with Fresenius Medical Care offerings like PhosLo and Velphoro, and with Shire’s Fosrenol. The company’s advantages stem from its hypoxia inducible factor platform that enables oral administration, its established supply and distribution agreements with the largest dialysis organizations serving the majority of patients, and its pipeline of novel mechanisms that address unmet needs in rare kidney diseases where few approved therapies exist.

Akebia Therapeutics serves dialysis patients, non dialysis dependent chronic kidney disease patients and the nephrologists who manage their care. The company’s products reach patients through contracts with major dialysis operators including DaVita Inc., Fresenius KidneyCare Group LLC, US Renal Care, Dialysis Clinic Inc. and Innovative Renal Care, which together provide care for 82% of the United States dialysis population. As of December 2025, approximately 290,000 dialysis patients in the United States had prescribing access to Vafseo through protocols established with these operators. Nephrologists prescribe Auryxia for non dialysis dependent patients with iron deficiency anemia, a group estimated to exceed 500,000 individuals in the United States. The company also works with health care providers to develop educational programs that support appropriate use of its therapies.

Investment Thesis

▲ Bull case

Vafseo launch showed a sixty% increase in patients on therapy quarter over quarter driven by broader prescriber engagement and the shift to observed dosing protocols across multiple dialysis organizations. The observed dosing approach improved first refill adherence to approximately eighty six% indicating better durability of therapy. This adoption trend is supported by growth in prescriber counts which rose twenty eight% compared with the prior quarter. The increase in patients on therapy occurred even though many new starts only contributed one month of treatment in the quarter suggesting future revenue will benefit from full treatment cycles. These factors together point to a faster than expected ramp in Vafseo utilization that the market may not be fully pricing in.
The VOCAL study being run at DaVita clinics will evaluate Vafseo dosed three times weekly and includes a substudy on red blood cell characteristics that could further differentiate the drug from standard ESAs. Top line data from VOCAL are expected by year end and could provide additional evidence of reduced hospitalization events and mortality risk. Complementing VOCAL the VOICE trial run by U S Renal Care will assess Vafseo versus standard of care on a hierarchical composite endpoint of all cause mortality and hospitalization rates with top line data expected in early 2027. Positive results from either trial would reinforce the findings of the recently published hierarchical composite endpoint analysis from the INNOVATE program. Such data could support label expansions and strengthen reimbursement arguments as Vafseo moves toward bundle inclusion.
Vafseo currently enjoys a temporary dual reimbursement advantage through the TDAPA add on payment which provides additional revenue beyond the standard dialysis bundle. The company is already preparing for the transition to full bundle inclusion slated for the beginning of 2027 when Vafseo will compete directly within the estimated one billion dollar ESA market for dialysis patients. Capturing even a modest share of this large market could generate meaningful revenue growth and improve long term profitability. The TDAPA period offers a window to build brand loyalty and clinical evidence that may ease the bundle transition. This structural advantage is not fully reflected in current valuation multiples.
The pipeline includes praliciguat a soluble guanylate cyclase stimulator being evaluated in focal segmental glomerulosclerosis with a goal of achieving a twenty% improvement in urine protein to creatinine ratio comparable to the recently approved sparsentan. Success in this Phase II study could lead to a Phase III program and potential partnership interest given the limited number of effective therapies in FSGS. Additionally AKB-097 a tissue targeted anti C3D complement inhibitor is slated to enter an open label basket trial in the second half of the year targeting IgA nephropathy lupus nephritis and C3 glomerulopathy. Early data suggest rapid tissue targeting and lower infection risk relative to existing complement inhibitors which could differentiate the asset in a crowded market. These programs provide near term catalysts that could unlock value beyond the current anemia franchise.
AKB-9090 is an internally developed HIF PH inhibitor designed to prevent acute kidney injury associated with cardiac surgery and is currently in a Phase I SAD MAD study in healthy volunteers. Top line data from this program are expected in early 2027 and could establish a proof of concept for a novel prophylactic indication in a high acuity setting. The acute kidney injury prevention market is relatively underserved with few approved therapies creating an opportunity for first mover advantage. Successful development could diversify revenue streams away from chronic dialysis dependence and reduce reliance on the anemia franchise. The safety profile observed in early trials will be critical but the mechanistic rationale supports a favorable risk benefit balance.

Vafseo launch showed a sixty% increase in patients on therapy quarter over quarter driven by broader prescriber engagement and the shift to observed dosing protocols across multiple dialysis organizations. The observed dosing approach improved first refill adherence to approximately eighty six% indicating better durability of therapy. This adoption trend is supported by growth in prescriber counts which rose twenty eight% compared with the prior quarter. The increase in patients on therapy occurred even though many new starts only contributed one month of treatment in the quarter suggesting future revenue will benefit from full treatment cycles. These factors together point to a faster than expected ramp in Vafseo utilization that the market may not be fully pricing in.
The VOCAL study being run at DaVita clinics will evaluate Vafseo dosed three times weekly and includes a substudy on red blood cell characteristics that could further differentiate the drug from standard ESAs. Top line data from VOCAL are expected by year end and could provide additional evidence of reduced hospitalization events and mortality risk. Complementing VOCAL the VOICE trial run by U S Renal Care will assess Vafseo versus standard of care on a hierarchical composite endpoint of all cause mortality and hospitalization rates with top line data expected in early 2027. Positive results from either trial would reinforce the findings of the recently published hierarchical composite endpoint analysis from the INNOVATE program. Such data could support label expansions and strengthen reimbursement arguments as Vafseo moves toward bundle inclusion.
Vafseo currently enjoys a temporary dual reimbursement advantage through the TDAPA add on payment which provides additional revenue beyond the standard dialysis bundle. The company is already preparing for the transition to full bundle inclusion slated for the beginning of 2027 when Vafseo will compete directly within the estimated one billion dollar ESA market for dialysis patients. Capturing even a modest share of this large market could generate meaningful revenue growth and improve long term profitability. The TDAPA period offers a window to build brand loyalty and clinical evidence that may ease the bundle transition. This structural advantage is not fully reflected in current valuation multiples.
The pipeline includes praliciguat a soluble guanylate cyclase stimulator being evaluated in focal segmental glomerulosclerosis with a goal of achieving a twenty% improvement in urine protein to creatinine ratio comparable to the recently approved sparsentan. Success in this Phase II study could lead to a Phase III program and potential partnership interest given the limited number of effective therapies in FSGS. Additionally AKB-097 a tissue targeted anti C3D complement inhibitor is slated to enter an open label basket trial in the second half of the year targeting IgA nephropathy lupus nephritis and C3 glomerulopathy. Early data suggest rapid tissue targeting and lower infection risk relative to existing complement inhibitors which could differentiate the asset in a crowded market. These programs provide near term catalysts that could unlock value beyond the current anemia franchise.
AKB-9090 is an internally developed HIF PH inhibitor designed to prevent acute kidney injury associated with cardiac surgery and is currently in a Phase I SAD MAD study in healthy volunteers. Top line data from this program are expected in early 2027 and could establish a proof of concept for a novel prophylactic indication in a high acuity setting. The acute kidney injury prevention market is relatively underserved with few approved therapies creating an opportunity for first mover advantage. Successful development could diversify revenue streams away from chronic dialysis dependence and reduce reliance on the anemia franchise. The safety profile observed in early trials will be critical but the mechanistic rationale supports a favorable risk benefit balance.

▼ Bear case

Auryxia net product revenues declined from forty three point eight million dollars in Q1 twenty twenty five to thirty six point two million dollars in Q1 twenty twenty six reflecting pressure from generic competition that includes an authorized generic and a newer generic entrant. The loss of this historically profitable product reduces overall cash flow and increases reliance on Vafseo to sustain profitability. Generic erosion is expected to continue throughout twenty twenty six which could accelerate the decline in total revenue if Vafseo growth does not offset the shortfall. Investors may be overestimating the ability of Vafseo alone to replace the contribution from Auryxia in the near term.
Vafseo uptake remains tightly linked to the adoption of observed dosing protocols by dialysis organizations with DaVita still operating under a QD regimen and only planning a shift to observed dosing in the second half of the year. If DaVita’s rollout is delayed or if physicians resist the change the potential patient pool from the largest dialysis provider may not be realized as quickly as anticipated. Slower than expected protocol adoption would directly limit the growth in patient starts and prescription volume that drove the sixty% quarter over quarter increase observed in Q1. The market may be assuming a more rapid transition than what the current commentary suggests.
The anemia management market is crowded with established erythropoiesis stimulating agents and several competing HIF PH inhibitors that are either approved or in late stage development. These alternatives offer comparable efficacy with established safety profiles and may limit Vafseo’s ability to command premium pricing or achieve significant market share. If competitors succeed in securing favorable formulary placement or bundle pricing advantages Vafseo could be relegated to a niche position despite its clinical differentiation. The company’s reliance on clinical data to differentiate may not be sufficient to overcome entrenched incumbent preferences.
Pipeline programs such as praliciguat in FSGS and AKB-097 in complement mediated diseases are still in early phases with enrollment targets of approximately sixty patients for the FSGS study and an open label basket trial for the complement inhibitor slated to start in the second half of the year. Recruitment in rare disease indications is often challenging and slower than projected which could delay readouts and increase development costs. Failure to meet efficacy endpoints such as a twenty% improvement in urine protein to creatinine ratio would diminish the perceived value of these assets and could lead to termination or partnership reluctance. The binary nature of early stage clinical trials creates substantial risk that is not fully captured by the current valuation.
The impending transition of Vafseo into the Medicare dialysis bundle at the start of twenty twenty seven will subject the drug to a fixed payment structure that could limit pricing flexibility and exert downward pressure on net realized revenue. Bundle inclusion often leads to intensified competition on cost effectiveness and may require additional discounts or rebates to maintain formulary access. If the bundle payment rate is set below current TDAPA supplemented levels the company could experience a step down in revenue per patient despite higher utilization. This reimbursement shift introduces uncertainty that may not be adequately reflected in near term guidance.

Auryxia net product revenues declined from forty three point eight million dollars in Q1 twenty twenty five to thirty six point two million dollars in Q1 twenty twenty six reflecting pressure from generic competition that includes an authorized generic and a newer generic entrant. The loss of this historically profitable product reduces overall cash flow and increases reliance on Vafseo to sustain profitability. Generic erosion is expected to continue throughout twenty twenty six which could accelerate the decline in total revenue if Vafseo growth does not offset the shortfall. Investors may be overestimating the ability of Vafseo alone to replace the contribution from Auryxia in the near term.
Vafseo uptake remains tightly linked to the adoption of observed dosing protocols by dialysis organizations with DaVita still operating under a QD regimen and only planning a shift to observed dosing in the second half of the year. If DaVita’s rollout is delayed or if physicians resist the change the potential patient pool from the largest dialysis provider may not be realized as quickly as anticipated. Slower than expected protocol adoption would directly limit the growth in patient starts and prescription volume that drove the sixty% quarter over quarter increase observed in Q1. The market may be assuming a more rapid transition than what the current commentary suggests.
The anemia management market is crowded with established erythropoiesis stimulating agents and several competing HIF PH inhibitors that are either approved or in late stage development. These alternatives offer comparable efficacy with established safety profiles and may limit Vafseo’s ability to command premium pricing or achieve significant market share. If competitors succeed in securing favorable formulary placement or bundle pricing advantages Vafseo could be relegated to a niche position despite its clinical differentiation. The company’s reliance on clinical data to differentiate may not be sufficient to overcome entrenched incumbent preferences.
Pipeline programs such as praliciguat in FSGS and AKB-097 in complement mediated diseases are still in early phases with enrollment targets of approximately sixty patients for the FSGS study and an open label basket trial for the complement inhibitor slated to start in the second half of the year. Recruitment in rare disease indications is often challenging and slower than projected which could delay readouts and increase development costs. Failure to meet efficacy endpoints such as a twenty% improvement in urine protein to creatinine ratio would diminish the perceived value of these assets and could lead to termination or partnership reluctance. The binary nature of early stage clinical trials creates substantial risk that is not fully captured by the current valuation.
The impending transition of Vafseo into the Medicare dialysis bundle at the start of twenty twenty seven will subject the drug to a fixed payment structure that could limit pricing flexibility and exert downward pressure on net realized revenue. Bundle inclusion often leads to intensified competition on cost effectiveness and may require additional discounts or rebates to maintain formulary access. If the bundle payment rate is set below current TDAPA supplemented levels the company could experience a step down in revenue per patient despite higher utilization. This reimbursement shift introduces uncertainty that may not be adequately reflected in near term guidance.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password